EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options

Piero Portincasa iD, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy, Agostino Di Ciaula iD

International Journal of Molecular Sciences · 22.05.2024 · 25 (11) · 5640

DOI: 10.3390/ijms25115640 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.05.2024. Verfasst von Piero Portincasa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinica Medica "A. Murri", Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari "Aldo Moro", 70124 Bari,…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 154-mal zitiert (Crossref) und nennt 350 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bari Aldo Moro (Italy), Universidade De Coimbra, Portugal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from “nonalcoholic fatty liver disease” (NAFLD) to “metabolic dysfunction-associated fatty liver disease” (MAFLD) and, finally, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut–liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansMetabolic DiseasesFatty LiverAnimals

Stichwörter der Autor:innen

MAFLDMASLDNAFLDNASHclinical trialsdrug therapyfatty liverliver fibrosis

Autor:innen und Institutionen

  • Clinica Medica "A. Murri", Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
  • Aboca S.p.a. Società Agricola, 52037 Sansepolcro, Italy.
  • Institut AllergoSan Pharmazeutische Produkte Forschungs- und Vertriebs GmbH, 8055 Graz, Austria.
  • Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Section of Gastroenterology, Department of Medicine, VA Boston Healthcare System, Boston, MA 02132, USA.

ORCID-Profile: Piero Portincasa, Agostino Di Ciaula

Förderung

  • University of Bari Aldo Moro (Italy)
  • Universidade De Coimbra, Portugal

Zitieren

APA

Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Di Ciaula, A. (2024). Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. International Journal of Molecular Sciences, 25(11), 5640. https://doi.org/10.3390/ijms25115640

Vancouver

Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. International Journal of Molecular Sciences. 2024;25(11):5640. doi:10.3390/ijms25115640

BibTeX
@article{Portincasa2024,
  author = {Portincasa, Piero and Khalil, Mohamad and Mahdi, Laura and Perniola, Valeria and Idone, Valeria and Graziani, Annarita and Baffy, Gyorgy and Di Ciaula, Agostino},
  title = {Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {11},
  pages = {5640},
  doi = {10.3390/ijms25115640}
}
Kostenlos starten →